MX2022014243A - Proteina de union al antigeno st2. - Google Patents
Proteina de union al antigeno st2.Info
- Publication number
- MX2022014243A MX2022014243A MX2022014243A MX2022014243A MX2022014243A MX 2022014243 A MX2022014243 A MX 2022014243A MX 2022014243 A MX2022014243 A MX 2022014243A MX 2022014243 A MX2022014243 A MX 2022014243A MX 2022014243 A MX2022014243 A MX 2022014243A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- antibodies
- binding protein
- binding fragments
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010397572 | 2020-05-12 | ||
| PCT/CN2021/093066 WO2021228091A1 (zh) | 2020-05-12 | 2021-05-11 | St2抗原结合蛋白 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014243A true MX2022014243A (es) | 2022-12-02 |
Family
ID=78525985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014243A MX2022014243A (es) | 2020-05-12 | 2021-05-11 | Proteina de union al antigeno st2. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230272086A1 (enExample) |
| EP (1) | EP4151654A4 (enExample) |
| JP (2) | JP7834654B2 (enExample) |
| KR (1) | KR20230010691A (enExample) |
| CN (5) | CN121949549A (enExample) |
| AU (1) | AU2021271960A1 (enExample) |
| BR (1) | BR112022022852A2 (enExample) |
| CA (1) | CA3178564A1 (enExample) |
| IL (1) | IL298075A (enExample) |
| MX (1) | MX2022014243A (enExample) |
| WO (1) | WO2021228091A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| CN117024595B (zh) * | 2023-10-08 | 2024-01-26 | 江西乐成欣生生物技术研究有限责任公司 | 抗人st2的单克隆抗体及其应用 |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
| WO2025210099A1 (en) | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9108652D0 (en) | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DK0671927T3 (da) | 1992-09-16 | 2003-04-22 | Us Gov Health & Human Serv | Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus |
| JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片 |
| AU1866895A (en) | 1994-01-04 | 1995-08-01 | Scripps Research Institute, The | Human monoclonal antibodies to herpes simplex virus and methods therefor |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| EP1097172A1 (en) | 1998-07-21 | 2001-05-09 | Genmab A/S | Anti hepatitis c virus antibody and uses thereof |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| CN101160324B (zh) | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
| US9090694B2 (en) * | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| RU2693084C2 (ru) * | 2014-01-10 | 2019-07-01 | Анаптисбайо, Инк. | Антитела, направленные против интерлейкина-33 (il-33) |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US10539572B2 (en) * | 2015-01-30 | 2020-01-21 | Salk Institute For Biological Studies | Compositions and methods for treating age-related diabetes and related disorders |
| CN108064236B (zh) * | 2015-03-31 | 2021-12-10 | 免疫医疗有限公司 | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 |
| RU2740309C2 (ru) * | 2016-04-27 | 2021-01-13 | Пфайзер Инк. | Антитела против il-33, композиции, способы и их применение |
| CN107446040B (zh) * | 2016-05-30 | 2021-01-12 | 深圳市安群生物工程有限公司 | 人st2抗原表位肽、抗原、抗体、试剂盒及应用 |
| SG11202104120VA (en) * | 2018-10-31 | 2021-05-28 | Delinia Inc | Multivalent regulatory t cell modulators |
| CN110357963B (zh) | 2019-07-31 | 2020-09-18 | 北京智仁美博生物科技有限公司 | 抗人st2抗体及其用途 |
| US10577424B1 (en) * | 2019-08-15 | 2020-03-03 | Beijing Mabworks Biotech Co., Ltd. | Antibodies binding VISTA and uses thereof |
| CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
-
2021
- 2021-05-11 AU AU2021271960A patent/AU2021271960A1/en active Pending
- 2021-05-11 CA CA3178564A patent/CA3178564A1/en active Pending
- 2021-05-11 CN CN202610045284.9A patent/CN121949549A/zh active Pending
- 2021-05-11 WO PCT/CN2021/093066 patent/WO2021228091A1/zh not_active Ceased
- 2021-05-11 IL IL298075A patent/IL298075A/en unknown
- 2021-05-11 CN CN202610045279.8A patent/CN121851171A/zh active Pending
- 2021-05-11 KR KR1020227043483A patent/KR20230010691A/ko active Pending
- 2021-05-11 BR BR112022022852A patent/BR112022022852A2/pt unknown
- 2021-05-11 CN CN202610045280.0A patent/CN121914272A/zh active Pending
- 2021-05-11 CN CN202180030957.9A patent/CN115461370B/zh active Active
- 2021-05-11 JP JP2022568971A patent/JP7834654B2/ja active Active
- 2021-05-11 CN CN202610045286.8A patent/CN121851172A/zh active Pending
- 2021-05-11 US US17/924,613 patent/US20230272086A1/en active Pending
- 2021-05-11 EP EP21803875.0A patent/EP4151654A4/en active Pending
- 2021-05-11 MX MX2022014243A patent/MX2022014243A/es unknown
-
2025
- 2025-12-02 JP JP2025218969A patent/JP2026048732A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN121949549A (zh) | 2026-05-01 |
| KR20230010691A (ko) | 2023-01-19 |
| CN115461370B (zh) | 2026-01-02 |
| CA3178564A1 (en) | 2021-11-18 |
| EP4151654A4 (en) | 2024-11-27 |
| JP2023525826A (ja) | 2023-06-19 |
| CN121851172A (zh) | 2026-04-14 |
| CN121851171A (zh) | 2026-04-14 |
| IL298075A (en) | 2023-01-01 |
| CN115461370A (zh) | 2022-12-09 |
| BR112022022852A2 (pt) | 2022-12-20 |
| WO2021228091A1 (zh) | 2021-11-18 |
| CN121914272A (zh) | 2026-04-24 |
| JP7834654B2 (ja) | 2026-03-24 |
| EP4151654A1 (en) | 2023-03-22 |
| US20230272086A1 (en) | 2023-08-31 |
| AU2021271960A1 (en) | 2023-02-02 |
| JP2026048732A (ja) | 2026-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200078B1 (ar) | أجسام مضادة خاصة بـ cd47 وpd-l1 | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| MX2025009209A (es) | Anticuerpos de b7-h4 y metodos para usarlos | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| NZ734803A (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| WO2020014097A8 (en) | Reagents and methods for treating cancer and autoimmune disease | |
| PH12022552520A1 (en) | Antibodies binding siglec15 and uses thereof | |
| AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| MX2024010983A (es) | Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control. | |
| ZA202201464B (en) | Anti-tigit antibodies and application thereof | |
| MY210018A (en) | Monoclonal antibody that binds specifically to gitr | |
| EP4279086A3 (en) | Compositions and methods for treating cancer with anti-cd19 immunotherapy | |
| WO2022006451A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies | |
| CN115461370A (zh) | St2抗原结合蛋白 | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
| EA202290208A1 (ru) | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ EGFRvIII, И ИХ ПРИМЕНЕНИЕ | |
| ZA202408388B (en) | Antibodies targeting sirp-alpha and uses thereof | |
| WO2020223392A3 (en) | Cancer associated antibody compositions and methods of use | |
| EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения | |
| MX2025003153A (es) | Anticuerpos anti-ccr8 | |
| WO2022067269A3 (en) | Antibodies against sars-cov-2 | |
| Woisetschläger et al. | In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her‐2/neu binding sites | |
| WO2023205186A3 (en) | Dna therapeutic encoding an antibody or antigen binding fragment | |
| MX2023007583A (es) | Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen. |